Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer’s D
Go back to Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer’s D| Arbios Systems, Inc. (NASDAQ: ABOS) | Delayed: 1.98 -0.08 (3.88%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.06 | 52 Week High | $0.23 | |||
| Open | $2.05 | 52 Week Low | $0.00 | |||
| Day High | $2.05 | P/E | N/A | |||
| Day Low | $1.90 | EPS | $0.00 | |||
| Volume | 541,639 | |||||



